Physician profile
Richmond J Ramirez
NPI 1124281332
$1,231.13
in general payments reported to CMS, 2019-2025
16 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $137 · 2021: $155 · 2022: $125 · 2023: $43.23 · 2024: $158 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $207.33 | 2019-2024 | |
| Insulet Corporation | $162.01 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $152.38 | 2022-2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $144.42 | 2025 | Monoferric |
| Viiv Healthcare Company | $119.19 | 2025 | Apretude |
| Teva Pharmaceuticals USA, INC. | $116.69 | 2020 | |
| Novartis Pharmaceuticals Corporation | $73.45 | 2024-2025 | |
| Galderma Laboratories, L.P. | $43.23 | 2023 | |
| Intra-Sana Laboratories | $37.46 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Corcept Therapeutics | $31.43 | 2025 | Korlym |
| Dexcom, INC. | $29.00 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $27.76 | 2025 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $27.68 | 2025 | Nexletol |
| Amarin Pharma, INC. | $21.65 | 2021 | |
| Gilead Sciences, INC. | $20.66 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $16.79 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richmond Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.